What is it?
CJC DAC refers to a class of drug affinity complexes developed to improve the treatment of Type 2 diabetes by enhancing the stability and efficacy of glucagon-like peptide 1 (GLP-1) analogues. These compounds are designed to resist degradation and provide prolonged therapeutic effects.
What does science research say?
For immediate release Phase I / II Preliminary Results of PC-DAC TM : Exendin-4 Trial for Type 2 Diabetes Demonstrate Excellent Tolerability and Positive Efficacy-PK / PD Data Supports Once-A-Week Dosing with Longer Dosing Intervals Possible
Summary: PC-DACTM: Exendin-4 shows excellent tolerability and positive efficacy in treating Type 2 diabetes, supporting once-a-week dosing with longer dosing intervals possible.
Link: Glucagon
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Summary: CJC-1131, a degradation-resistant GLP-1 analogue conjugated to albumin, effectively lowers glucose levels and activates the GLP-1 receptor in vivo, offering a new approach for prolonged GLP-1R signaling.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Summary: CJC-1295, a long-acting growth hormone-releasing hormone analog, effectively increases growth hormone and IGF-I levels in healthy adults, with potential therapeutic utility.
Link: Oxford Academic
What do user think?
*Based on large scale analysis of publicly available user experiences, the higher it is the better overall opinions of users on efficiency, safety, availability, etc.
Category: Mostly Effective
Many users report boosted GH/IGF-1 and physique benefits, although cost and individual variability keep it below โeffective.โ
Main insights
Effects |
|
Effectiveness |
|
Dosage & Administration |
|
Side Effects |
|
Availability & Sourcing |
|